Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Identifieur interne : 003835 ( Main/Exploration ); précédent : 003834; suivant : 003836Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Auteurs : Marie Levade [France] ; Elodie David [France] ; Cédric Garcia [France] ; Pierre-Alexandre Laurent [France] ; Sarah Cadot [France] ; Anne-Sophie Michallet [France] ; Jean-Claude Bordet [France] ; Constantine Tam ; Pierre Sié [France] ; Loïc Ysebaert [France] ; Bernard Payrastre [France]Source :
- Blood [ 1528-0020 ] ; 2014.
Descripteurs français
- KwdFr :
- Activation plaquettaire, Adhésivité plaquettaire, Antienzymes (), Collagène (), Diméthylsulfoxyde (), Facteur de von Willebrand (), Humains, Hémostase, Héparine (), Phospholipase C gamma (), Phosphorylation, Plaquettes (), Plaquettes (cytologie), Pyrazoles (), Pyrimidines (), Résistance au cisaillement, Études longitudinales.
- MESH :
- cytologie : Plaquettes.
- Activation plaquettaire, Adhésivité plaquettaire, Antienzymes, Collagène, Diméthylsulfoxyde, Facteur de von Willebrand, Humains, Hémostase, Héparine, Phospholipase C gamma, Phosphorylation, Plaquettes, Pyrazoles, Pyrimidines, Résistance au cisaillement, Études longitudinales.
English descriptors
- KwdEn :
- Blood Platelets (cytology), Blood Platelets (drug effects), Collagen (chemistry), Dimethyl Sulfoxide (chemistry), Enzyme Inhibitors (chemistry), Hemostasis, Heparin (chemistry), Humans, Longitudinal Studies, Phospholipase C gamma (chemistry), Phosphorylation, Platelet Activation, Platelet Adhesiveness, Pyrazoles (chemistry), Pyrimidines (chemistry), Shear Strength, von Willebrand Factor (chemistry).
- MESH :
- chemical , chemistry : Collagen, Dimethyl Sulfoxide, Enzyme Inhibitors, Heparin, Phospholipase C gamma, Pyrazoles, Pyrimidines, von Willebrand Factor.
- cytology : Blood Platelets.
- drug effects : Blood Platelets.
- Hemostasis, Humans, Longitudinal Studies, Phosphorylation, Platelet Activation, Platelet Adhesiveness, Shear Strength.
Abstract
The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recently demonstrated high efficiency in patients with relapsed B-cell malignancies. Occurrence of bleeding events has been reported in a subgroup of ibrutinib-treated patients. We demonstrate that ibrutinib selectively inhibits platelet signaling and functions downstream of the collagen receptor glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow. A longitudinal study of 14 patients indicated a correlation between occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arterial flow. The addition of 50% untreated platelets was sufficient to efficiently reverse the effects of ibrutinib, and platelet functions recovered after treatment interruption as physiological platelet renewal occurred. These data have important clinical implications and provide a basis for hemostasis management during ibrutinib treatment.
DOI: 10.1182/blood-2014-06-583294
PubMed: 25305202
Affiliations:
- France
- Auvergne-Rhône-Alpes, Midi-Pyrénées, Occitanie (région administrative), Rhône-Alpes
- Lyon, Toulouse
- Université Toulouse III - Paul Sabatier
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003225
- to stream PubMed, to step Curation: 003115
- to stream PubMed, to step Checkpoint: 003115
- to stream Ncbi, to step Merge: 001E96
- to stream Ncbi, to step Curation: 001E96
- to stream Ncbi, to step Checkpoint: 001E96
- to stream Main, to step Merge: 003869
- to stream Main, to step Curation: 003835
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.</title><author><name sortKey="Levade, Marie" sort="Levade, Marie" uniqKey="Levade M" first="Marie" last="Levade">Marie Levade</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author><author><name sortKey="David, Elodie" sort="David, Elodie" uniqKey="David E" first="Elodie" last="David">Elodie David</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Garcia, Cedric" sort="Garcia, Cedric" uniqKey="Garcia C" first="Cédric" last="Garcia">Cédric Garcia</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Laurent, Pierre Alexandre" sort="Laurent, Pierre Alexandre" uniqKey="Laurent P" first="Pierre-Alexandre" last="Laurent">Pierre-Alexandre Laurent</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author><author><name sortKey="Cadot, Sarah" sort="Cadot, Sarah" uniqKey="Cadot S" first="Sarah" last="Cadot">Sarah Cadot</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea><wicri:noRegion>Pierre Bénite</wicri:noRegion><wicri:noRegion>Pierre Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Bordet, Jean Claude" sort="Bordet, Jean Claude" uniqKey="Bordet J" first="Jean-Claude" last="Bordet">Jean-Claude Bordet</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name><affiliation><nlm:affiliation>Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Sie, Pierre" sort="Sie, Pierre" uniqKey="Sie P" first="Pierre" last="Sié">Pierre Sié</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author><author><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loïc" last="Ysebaert">Loïc Ysebaert</name><affiliation wicri:level="3"><nlm:affiliation>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Payrastre, Bernard" sort="Payrastre, Bernard" uniqKey="Payrastre B" first="Bernard" last="Payrastre">Bernard Payrastre</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25305202</idno><idno type="pmid">25305202</idno><idno type="doi">10.1182/blood-2014-06-583294</idno><idno type="wicri:Area/PubMed/Corpus">003225</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003225</idno><idno type="wicri:Area/PubMed/Curation">003115</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003115</idno><idno type="wicri:Area/PubMed/Checkpoint">003115</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003115</idno><idno type="wicri:Area/Ncbi/Merge">001E96</idno><idno type="wicri:Area/Ncbi/Curation">001E96</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E96</idno><idno type="wicri:Area/Main/Merge">003869</idno><idno type="wicri:Area/Main/Curation">003835</idno><idno type="wicri:Area/Main/Exploration">003835</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.</title><author><name sortKey="Levade, Marie" sort="Levade, Marie" uniqKey="Levade M" first="Marie" last="Levade">Marie Levade</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author><author><name sortKey="David, Elodie" sort="David, Elodie" uniqKey="David E" first="Elodie" last="David">Elodie David</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Garcia, Cedric" sort="Garcia, Cedric" uniqKey="Garcia C" first="Cédric" last="Garcia">Cédric Garcia</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Laurent, Pierre Alexandre" sort="Laurent, Pierre Alexandre" uniqKey="Laurent P" first="Pierre-Alexandre" last="Laurent">Pierre-Alexandre Laurent</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author><author><name sortKey="Cadot, Sarah" sort="Cadot, Sarah" uniqKey="Cadot S" first="Sarah" last="Cadot">Sarah Cadot</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite</wicri:regionArea><wicri:noRegion>Pierre Bénite</wicri:noRegion><wicri:noRegion>Pierre Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Bordet, Jean Claude" sort="Bordet, Jean Claude" uniqKey="Bordet J" first="Jean-Claude" last="Bordet">Jean-Claude Bordet</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name><affiliation><nlm:affiliation>Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Sie, Pierre" sort="Sie, Pierre" uniqKey="Sie P" first="Pierre" last="Sié">Pierre Sié</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author><author><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loïc" last="Ysebaert">Loïc Ysebaert</name><affiliation wicri:level="3"><nlm:affiliation>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Payrastre, Bernard" sort="Payrastre, Bernard" uniqKey="Payrastre B" first="Bernard" last="Payrastre">Bernard Payrastre</name><affiliation wicri:level="4"><nlm:affiliation>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France; Laboratoire d'Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement><settlement type="city">Toulouse</settlement></placeName><orgName type="university">Université Toulouse III - Paul Sabatier</orgName></affiliation></author></analytic><series><title level="j">Blood</title><idno type="eISSN">1528-0020</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Platelets (cytology)</term><term>Blood Platelets (drug effects)</term><term>Collagen (chemistry)</term><term>Dimethyl Sulfoxide (chemistry)</term><term>Enzyme Inhibitors (chemistry)</term><term>Hemostasis</term><term>Heparin (chemistry)</term><term>Humans</term><term>Longitudinal Studies</term><term>Phospholipase C gamma (chemistry)</term><term>Phosphorylation</term><term>Platelet Activation</term><term>Platelet Adhesiveness</term><term>Pyrazoles (chemistry)</term><term>Pyrimidines (chemistry)</term><term>Shear Strength</term><term>von Willebrand Factor (chemistry)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation plaquettaire</term><term>Adhésivité plaquettaire</term><term>Antienzymes ()</term><term>Collagène ()</term><term>Diméthylsulfoxyde ()</term><term>Facteur de von Willebrand ()</term><term>Humains</term><term>Hémostase</term><term>Héparine ()</term><term>Phospholipase C gamma ()</term><term>Phosphorylation</term><term>Plaquettes ()</term><term>Plaquettes (cytologie)</term><term>Pyrazoles ()</term><term>Pyrimidines ()</term><term>Résistance au cisaillement</term><term>Études longitudinales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Collagen</term><term>Dimethyl Sulfoxide</term><term>Enzyme Inhibitors</term><term>Heparin</term><term>Phospholipase C gamma</term><term>Pyrazoles</term><term>Pyrimidines</term><term>von Willebrand Factor</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Plaquettes</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Blood Platelets</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Platelets</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Hemostasis</term><term>Humans</term><term>Longitudinal Studies</term><term>Phosphorylation</term><term>Platelet Activation</term><term>Platelet Adhesiveness</term><term>Shear Strength</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation plaquettaire</term><term>Adhésivité plaquettaire</term><term>Antienzymes</term><term>Collagène</term><term>Diméthylsulfoxyde</term><term>Facteur de von Willebrand</term><term>Humains</term><term>Hémostase</term><term>Héparine</term><term>Phospholipase C gamma</term><term>Phosphorylation</term><term>Plaquettes</term><term>Pyrazoles</term><term>Pyrimidines</term><term>Résistance au cisaillement</term><term>Études longitudinales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recently demonstrated high efficiency in patients with relapsed B-cell malignancies. Occurrence of bleeding events has been reported in a subgroup of ibrutinib-treated patients. We demonstrate that ibrutinib selectively inhibits platelet signaling and functions downstream of the collagen receptor glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow. A longitudinal study of 14 patients indicated a correlation between occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet-rich plasma and firm adhesion on VWF under arterial flow. The addition of 50% untreated platelets was sufficient to efficiently reverse the effects of ibrutinib, and platelet functions recovered after treatment interruption as physiological platelet renewal occurred. These data have important clinical implications and provide a basis for hemostasis management during ibrutinib treatment.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li></orgName></list><tree><noCountry><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Levade, Marie" sort="Levade, Marie" uniqKey="Levade M" first="Marie" last="Levade">Marie Levade</name></region><name sortKey="Bordet, Jean Claude" sort="Bordet, Jean Claude" uniqKey="Bordet J" first="Jean-Claude" last="Bordet">Jean-Claude Bordet</name><name sortKey="Cadot, Sarah" sort="Cadot, Sarah" uniqKey="Cadot S" first="Sarah" last="Cadot">Sarah Cadot</name><name sortKey="David, Elodie" sort="David, Elodie" uniqKey="David E" first="Elodie" last="David">Elodie David</name><name sortKey="Garcia, Cedric" sort="Garcia, Cedric" uniqKey="Garcia C" first="Cédric" last="Garcia">Cédric Garcia</name><name sortKey="Laurent, Pierre Alexandre" sort="Laurent, Pierre Alexandre" uniqKey="Laurent P" first="Pierre-Alexandre" last="Laurent">Pierre-Alexandre Laurent</name><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name><name sortKey="Payrastre, Bernard" sort="Payrastre, Bernard" uniqKey="Payrastre B" first="Bernard" last="Payrastre">Bernard Payrastre</name><name sortKey="Sie, Pierre" sort="Sie, Pierre" uniqKey="Sie P" first="Pierre" last="Sié">Pierre Sié</name><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loïc" last="Ysebaert">Loïc Ysebaert</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003835 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003835 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25305202
|texte= Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25305202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |